How to transfer my Wegovy prescription to California

The short answer is yes—you can legally obtain GLP-1 weight loss medications like Wegovy, Ozempic, or Mounjaro through telehealth in the United States. But the specifics depend on where you live, who prescribes your medication, and whether you meet clinical criteria for treatment.

If you’ve been considering telehealth for weight management, you’re not alone. Millions of Americans are turning to virtual care for obesity treatment, drawn by the convenience, privacy, and growing availability of highly effective medications. Yet navigating the legal landscape can feel overwhelming, especially with state-specific rules and evolving federal regulations.

This guide breaks down everything you need to know about accessing weight loss medications via telehealth—from federal and state regulations to provider qualifications, patient eligibility, and what to expect during your virtual visit.

Understanding Federal Telehealth Rules for Weight Loss Medications

Why GLP-1 Medications Don’t Require an In-Person Visit Under Federal Law

Unlike controlled substances such as Adderall or opioids, GLP-1 medications (semaglutide and tirzepatide) are not scheduled drugs. This means the federal Ryan Haight Act—which normally requires an in-person exam before prescribing controlled substances via telemedicine—does not apply to weight loss medications like Wegovy, Ozempic, or Mounjaro.

From a federal standpoint, a licensed healthcare provider can evaluate you through a live video consultation and send your prescription electronically to a pharmacy, as long as a valid patient-provider relationship is established. This has been the case even before the COVID-19 pandemic, though telehealth adoption for weight management surged dramatically during and after 2020.

The DEA’s COVID-Era Flexibility (and What It Means for You)

During the pandemic, the Drug Enforcement Administration (DEA) temporarily waived in-person requirements for all prescriptions—including controlled substances—to expand access to care. As of December 2025, this flexibility has been extended through December 31, 2025, giving regulators more time to develop permanent telemedicine rules.

While this extension primarily affects medications like stimulants for ADHD or buprenorphine for addiction treatment, it reinforces a broader trend: telehealth is here to stay, and federal agencies are working to support safe, accessible virtual prescribing across the board.

For patients seeking weight loss treatment, the takeaway is simple: federal law does not restrict your ability to receive GLP-1 medications via telehealth. However, state laws add an additional layer of requirements—and that’s where things get more nuanced.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State-by-State Telehealth Rules: What You Need to Know

While federal law permits telehealth prescribing of weight loss medications, each state sets its own standards for how telemedicine must be practiced. Some states require an initial in-person visit, mandate specific follow-up schedules, or impose documentation requirements that go beyond federal minimums.

Below is a detailed breakdown of telehealth rules in key states where Klarity Health operates. We’ve focused on three critical factors:

1. In-Person Requirements: Does the state require a physical exam before or during treatment?
2. Provider Qualifications: Can Nurse Practitioners (NPs) and Physician Assistants (PAs) prescribe independently, or do they need physician oversight?
3. Follow-Up & Monitoring: Are there mandated check-ins or documentation standards?

States with Initial In-Person Exam Requirements

Several states require patients to undergo an initial in-person evaluation before starting weight loss medication via telehealth. These rules are typically designed to ensure thorough baseline assessments (height, weight, labs, medical history) and reduce the risk of inappropriate prescribing.

Arkansas: One of the most restrictive states for telemedicine, Arkansas mandates an initial in-person exam to establish a valid patient-provider relationship. After that first visit, follow-up care can be conducted via telehealth. Nurse Practitioners must work under a collaborative agreement with a physician.

Delaware: Requires an initial physical exam in person before prescribing weight loss medications. Once the relationship is established, subsequent care can be managed remotely. NPs in Delaware can practice independently after two years of collaborative experience.

Georgia: State law requires an in-person exam prior to prescribing obesity medications. A notable 2024 update allows NPs and PAs to prescribe Schedule II controlled substances (like stimulants) with physician delegation—previously forbidden. For GLP-1 weight loss drugs, NPs can prescribe under a collaborative agreement.

Mississippi: An initial in-person evaluation is expected for weight management therapy. Mississippi is currently considering legislation to grant NPs full practice authority, which would expand telehealth access. For now, NPs must collaborate with a physician.

New Jersey: Among the strictest states. New Jersey’s medical board requires a comprehensive initial evaluation that includes a physical exam, laboratory work, psychological screening, and a personalized diet and exercise plan. Providers must document informed consent covering risks like GI side effects and potential complications. NPs operate under joint protocols with physicians (full practice authority legislation is pending but not yet passed).

North Dakota: Expects an initial hands-on evaluation for weight loss treatment, per state medical board guidance. After the baseline visit, telehealth follow-ups are permitted. North Dakota is a full practice authority state for NPs, so nurse practitioners can prescribe independently once the initial exam is completed.

South Carolina: Requires an initial in-person visit and periodic evaluations. NPs and PAs can prescribe with physician oversight (NP independence bills have stalled in recent sessions). Follow-ups can be conducted via telehealth after the initial assessment.

Texas: Texas has particularly strict oversight. Standard of care typically requires an initial in-person exam before prescribing weight loss medications. NPs and PAs cannot practice independently—they must operate under a physician delegation agreement. Texas law explicitly prohibits NPs from prescribing certain controlled substances without physician oversight, though GLP-1s (being non-controlled) can be prescribed under delegation. Patients should expect thorough documentation and regular follow-up.

Utah: Encourages an initial in-person exam, though telehealth is widely embraced. Utah granted NPs full practice authority in 2023, so after an initial evaluation, NPs can manage weight loss treatment independently.

Virginia: Virginia’s Board of Medicine requires an initial physical exam, laboratory tests, and a personalized lifestyle plan before prescribing any weight-loss medication. A follow-up visit within 30 days of starting therapy is mandated. After these requirements are met, ongoing care can be provided via telehealth. NPs in Virginia have autonomous practice authority after two years of collaborative experience.

States That Allow Telehealth Without an In-Person Visit

Many states have embraced telemedicine without mandating an initial in-person exam for weight loss medications. In these states, a thorough virtual evaluation (including medical history, self-reported measurements, and video consultation) is sufficient to establish a patient-provider relationship and prescribe GLP-1 medications.

California: Explicitly permits telehealth exams to establish a valid relationship—no in-person visit required. Nurse Practitioners in California gained full practice authority in 2023 (after three years of experience), significantly expanding telehealth access. Providers must still meet standard-of-care requirements: comprehensive evaluation, documentation, and follow-up.

Connecticut: No in-person mandate. Connecticut law requires that obesity treatment include behavioral counseling and a diet/exercise plan alongside medication. NPs can practice independently after three years of collaboration.

Florida: Does not require an in-person physical exam for telehealth prescribing of GLP-1 medications. However, Florida imposes specific conditions: patients must have a BMI ≥30, and follow-up visits are required at least every three months during treatment. NPs have limited independence (primarily in primary care settings), so many telehealth providers use physician oversight for weight management.

Illinois: Allows telehealth prescribing without an in-person visit. Illinois mandates e-prescribing for all medications (effective since 2023), meaning your GLP-1 prescription will be sent electronically to your pharmacy. NPs must work under a written collaborative agreement with a physician.

New York: Permits telehealth exams to establish a patient relationship—no in-person requirement. NPs in New York have full practice authority after 3,600 hours of experience. The state has mandatory e-prescribing for all medications, including GLP-1s.

Pennsylvania: No in-person mandate for telehealth weight loss prescribing. Pennsylvania’s NP independence law (enacted in 2016) is still awaiting full implementation; as of 2025, NPs continue to require physician collaboration.

Washington: A pioneer in telehealth, Washington has no in-person exam requirement and allows NPs full practice authority. The state’s My Health My Data Act (2023) imposes strict privacy protections for telehealth providers—particularly important given the sensitive nature of weight and health data.

States with Special Documentation or Follow-Up Requirements

Even in states that don’t require an initial in-person visit, some impose additional safeguards to ensure patient safety.

Connecticut: Mandates that weight loss treatment include behavioral counseling and a structured diet/exercise plan, not just medication.

Florida: Requires follow-up visits at least every three months during treatment. This is stricter than many other states and ensures ongoing monitoring for side effects and efficacy.

Virginia: Requires a follow-up appointment within 30 days of starting medication, in addition to the initial comprehensive evaluation. Ongoing visits can be conducted via telehealth after these requirements are met.

New Jersey: Demands extensive upfront documentation, including informed consent forms that detail risks (e.g., pancreatitis, gallstones, GI side effects) and alternatives to medication.

Who Can Prescribe Weight Loss Medications Via Telehealth?

Physicians (MDs and DOs)

All states allow licensed physicians (MDs and DOs) to prescribe GLP-1 weight loss medications via telehealth, provided they hold a valid license in the state where the patient is located. Physicians are considered the ‘gold standard’ prescribers and face no additional restrictions beyond meeting state telemedicine requirements.

Nurse Practitioners (NPs)

Nurse Practitioners are playing an increasingly important role in telehealth weight management, but their prescribing authority varies significantly by state.

Full Practice Authority States: In these states, NPs can prescribe independently after meeting experience requirements (typically 2-3 years of collaborative practice). Examples include:

• California
• Washington
• New York
• Utah
• North Dakota
• Connecticut
• Delaware
• Virginia

Collaborative/Supervisory States: NPs can prescribe but must operate under a physician agreement or protocol. Examples include:

• Texas
• Florida
• Georgia
• Pennsylvania
• Illinois
• South Carolina
• Mississippi

Restricted States: A small number of states impose additional limits on NP prescribing (especially for controlled substances). However, since GLP-1 medications are non-controlled, NPs can typically prescribe them with appropriate oversight.

Physician Assistants (PAs)

Physician Assistants can prescribe GLP-1 medications in all states, but like NPs, they generally require a supervising or collaborating physician. The level of autonomy varies:

• In some states, PAs have considerable independence in day-to-day prescribing decisions.
• In others (like Texas), PAs must operate under a formal delegation agreement with explicit scope-of-practice limits.

What This Means for Patients

When you book a telehealth appointment for weight loss, you may see an MD, DO, NP, or PA depending on the provider’s credentials and your state’s laws. All of these practitioners are fully qualified to prescribe GLP-1 medications, as long as they’re licensed in your state and operating within legal scope.

At Klarity Health, we ensure all providers meet state licensing requirements and maintain collaborative agreements where necessary. You can feel confident that your prescriber—whether a physician or advanced practice provider—has the legal authority and clinical expertise to manage your weight loss treatment safely.

What to Expect During a Telehealth Weight Loss Consultation

Step 1: Initial Assessment and Medical History

Your first telehealth visit will involve a comprehensive evaluation. Expect to answer detailed questions about:

• Current weight and height (used to calculate BMI)
• Medical history: chronic conditions like diabetes, hypertension, thyroid disorders
• Medication list: current prescriptions and supplements
• Previous weight loss attempts: diet programs, exercise routines, prior medications
• Mental health screening: depression, anxiety, eating disorders
• Family history: obesity, diabetes, thyroid cancer (important for GLP-1 safety)
• Lifestyle factors: diet, physical activity, sleep, stress

Many telehealth platforms require you to upload a recent photo or video to verify your identity and allow the provider to conduct a visual assessment.

Step 2: Determining Eligibility

GLP-1 medications are FDA-approved for adults with:

• BMI ≥30 (clinical obesity), OR
• BMI ≥27 with at least one weight-related comorbidity (e.g., Type 2 diabetes, hypertension, dyslipidemia, sleep apnea)

Your provider will also screen for contraindications, including:

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)—all GLP-1s carry an FDA boxed warning for thyroid tumors
• Pregnancy or planning to become pregnant (must discontinue 2 months before conception)
• History of pancreatitis
• Severe gastrointestinal disorders (e.g., gastroparesis, inflammatory bowel disease)
• Active gallbladder disease

If you meet eligibility criteria and have no contraindications, your provider will discuss treatment options.

Step 3: Discussing Medication Options and Risks

Your provider will explain the differences between:

• Wegovy (semaglutide 2.4mg): FDA-approved specifically for weight loss
• Ozempic (semaglutide 0.5-1mg): FDA-approved for Type 2 diabetes; used off-label for weight loss
• Mounjaro/Zepbound (tirzepatide): Dual GLP-1/GIP agonist; Mounjaro is approved for diabetes, Zepbound for obesity

You’ll also review:

• Common side effects: Nausea, vomiting, diarrhea, constipation, abdominal pain (usually mild and improve over time)
• Serious risks: Pancreatitis, gallstones, kidney problems, allergic reactions
• Lifestyle requirements: GLP-1s work best when combined with reduced-calorie diet and increased physical activity

Your provider will obtain informed consent—especially important in states like New Jersey and Virginia, where this is legally mandated.

Step 4: Creating a Treatment Plan

If you’re approved, your provider will:

• Prescribe a starting dose (typically the lowest dose to minimize side effects)
• Schedule a follow-up appointment (often within 4 weeks to assess tolerance and adjust dose)
• Provide injection training (all GLP-1s are self-administered subcutaneous injections)
• Send your prescription electronically to your preferred pharmacy

Your treatment plan will include:

• Dietary guidance: calorie targets, portion control, balanced macronutrients
• Exercise recommendations: at least 150 minutes/week of moderate activity
• Behavioral support: strategies for mindful eating, stress management, sleep hygiene

Step 5: Ongoing Monitoring and Follow-Up

Telehealth weight loss programs emphasize regular follow-up to ensure safety and efficacy:

• Month 1: Check-in to assess side effects and tolerance
• Months 2-3: Dose titration (gradual increases based on response and side effects)
• Every 2-3 months: Weight checks, medication adjustments, lifestyle counseling
• Annual labs: Metabolic panel, A1C (if diabetic), lipid panel, kidney function

Some states mandate specific follow-up schedules:

• Florida: At least every 3 months
• Virginia: Within 30 days of starting therapy

Missing follow-up appointments may result in your provider pausing refills until you complete a check-in.

Common Misconceptions About Telehealth Weight Loss Medications

Misconception #1: ‘Anyone Can Get Ozempic Online’

Reality: Reputable telehealth providers have strict eligibility criteria. You must have a clinical diagnosis of obesity (BMI ≥30) or be overweight (BMI ≥27) with significant comorbidities. Providers will not prescribe GLP-1s for cosmetic weight loss or to patients who don’t meet medical criteria.

Misconception #2: ‘Telehealth Prescriptions Are Less Safe Than In-Person’

Reality: When conducted properly, telehealth evaluations meet the same standard of care as in-person visits. Providers review medical history, assess contraindications, and monitor patients through video consultations and lab work. Many telehealth platforms (like Klarity Health) offer more frequent check-ins than traditional clinics, improving safety and outcomes.

Misconception #3: ‘I Can Get a Year’s Supply Without Follow-Up’

Reality: Most telehealth providers prescribe 30-day supplies initially, with refills contingent on follow-up appointments. This ensures ongoing monitoring for side effects and dose adjustments. Long-term prescriptions (90 days) are typically reserved for patients who’ve been stable on treatment for several months.

Misconception #4: ‘Compounded Semaglutide Is the Same as Wegovy’

Reality: In May 2025, the FDA banned most compounding of semaglutide for weight loss after declaring the Wegovy shortage resolved. Compounded versions are not FDA-approved and may have inconsistent dosing or purity. Stick with brand-name or FDA-approved generic medications dispensed through licensed pharmacies.

Misconception #5: ‘GLP-1 Medications Are ‘Diet Pills’ That Work Overnight’

Reality: GLP-1 agonists are powerful tools for chronic weight management, but they’re not quick fixes. Expect gradual weight loss over several months (typically 10-15% of body weight over 6-12 months). Results require commitment to lifestyle changes—medication alone is not enough.

Red Flags: How to Spot Illegitimate Telehealth Providers

The popularity of GLP-1 medications has unfortunately attracted unscrupulous operators. Watch out for these warning signs:

🚩 Red Flag #1: Guaranteed Prescriptions Without Evaluation

Any service that promises you’ll get a prescription without a comprehensive medical assessment is breaking the law. Legitimate providers may determine you’re not a candidate based on your health profile.

🚩 Red Flag #2: Selling Compounded or ‘Generic’ Semaglutide

Since the FDA’s 2025 ban on routine compounding, any provider offering compounded GLP-1s (except in very limited circumstances) is operating in violation of federal rules. Be especially wary of overseas pharmacies or suspiciously cheap ‘generic’ versions.

🚩 Red Flag #3: No Follow-Up or Monitoring

Reputable telehealth programs require regular check-ins. If a provider gives you months of medication upfront with no plan for follow-up, that’s a major red flag.

🚩 Red Flag #4: Unclear Provider Credentials

You should always know who your prescriber is and verify they’re licensed in your state. If a website doesn’t clearly list provider names, credentials, or state licenses, look elsewhere.

🚩 Red Flag #5: Pressure to Waive Rights or Sign Broad Liability Releases

While informed consent is standard, be cautious of services that ask you to waive your right to sue for malpractice or sign overly broad liability releases. This suggests the provider isn’t confident in their own safety standards.

✅ What to Look for Instead

Choose telehealth providers that:

• Require live video consultations (not just questionnaires)
• Employ licensed MDs, DOs, NPs, or PAs with verifiable credentials
• Conduct thorough medical histories and contraindication screenings
• Schedule regular follow-ups and monitor your progress
• Prescribe only FDA-approved, brand-name medications through licensed pharmacies
• Are transparent about pricing, provider qualifications, and state licensing
• Offer clear contact information and customer support

Klarity Health meets all these standards, connecting you with licensed, experienced providers who specialize in weight management and mental health care.

How Klarity Health Supports Your Telehealth Weight Loss Journey

At Klarity Health, we’ve designed our telehealth platform to make accessing evidence-based weight loss treatment safe, convenient, and affordable—without compromising on quality of care.

🩺 Comprehensive Evaluations by Licensed Providers

Every Klarity patient meets with a licensed healthcare provider (MD, DO, NP, or PA) via live video consultation. Our providers are licensed in your state and trained in obesity medicine. We don’t use automated questionnaires or ‘pill mills’—your provider will conduct a thorough assessment, review your medical history, and create a personalized treatment plan.

💰 Transparent Pricing: Insurance and Cash Pay Options

We accept most major insurance plans and offer affordable cash-pay options for patients without coverage. You’ll always know the cost upfront—no surprise bills or hidden fees. Medication costs vary by pharmacy and insurance, but our team can help you find the most affordable option (including manufacturer savings programs and pharmacy discounts).

📅 Flexible Scheduling and Fast Appointments

Most patients can schedule an initial consultation within 1-2 days. Follow-up appointments are easy to book via our online platform, and we offer evening and weekend hours to accommodate your schedule.

🔒 Privacy and HIPAA Compliance

Your health information is protected by strict HIPAA standards. Our platform uses encrypted video and secure messaging to ensure your data stays private. In states with additional privacy laws (like Washington’s My Health My Data Act), we meet or exceed all requirements.

📦 Same-Day Electronic Prescriptions

If your provider determines you’re a candidate for GLP-1 medication, they’ll send your prescription electronically to your preferred pharmacy—often the same day as your appointment. You can pick up your medication or have it delivered, depending on pharmacy options.

🔄 Ongoing Support and Monitoring

Weight loss is a journey, not a one-time event. Klarity provides:

• Regular follow-up appointments to monitor progress and adjust treatment
• 24/7 messaging with your care team for questions between visits
• Lifestyle coaching and resources to support diet and exercise goals
• Lab coordination when needed (we can order labs and review results virtually)

🌎 Available in 17 States (and Growing)

Klarity currently serves patients in: Arkansas, California, Connecticut, Delaware, Florida, Georgia, Illinois, Mississippi, New Jersey, New York, North Dakota, Pennsylvania, South Carolina, Texas, Utah, Virginia, and Washington. We’re constantly expanding to new states—check our website for the latest availability.

Frequently Asked Questions About Telehealth Weight Loss Medications

Can I get Wegovy or Ozempic through telehealth if I don’t have diabetes?

Yes—if you meet obesity criteria (BMI ≥30 or ≥27 with comorbidities). Wegovy is specifically FDA-approved for weight loss in non-diabetic patients. Ozempic is FDA-approved for Type 2 diabetes but is commonly prescribed off-label for weight loss. Your provider will document the off-label rationale and obtain informed consent.

Do I need to have an in-person visit first?

It depends on your state. In states like California, Washington, Illinois, and New York, you can complete the entire process via telehealth—no in-person visit required. In states like Arkansas, Georgia, Texas, and New Jersey, you may need an initial in-person exam. Check the state-by-state table in this article for details.

How much do GLP-1 medications cost?

With insurance: Many plans now cover Wegovy or Zepbound for obesity, often with copays ranging from $25-$250/month (varies by plan). Ozempic (when used off-label for weight loss) may not be covered by insurance.

Without insurance (cash pay): Retail prices are approximately:

• Wegovy: $1,300-$1,600/month
• Ozempic: $900-$1,200/month
• Mounjaro/Zepbound: $1,000-$1,400/month

Many manufacturers offer savings cards that can reduce out-of-pocket costs significantly (sometimes to as low as $25-$50/month for eligible patients).

How long will I need to take these medications?

GLP-1 medications are typically prescribed for long-term use (months to years) because obesity is a chronic condition. Most patients regain weight if they stop the medication without maintaining lifestyle changes. Your provider will work with you to determine the best duration based on your goals and response to treatment.

What if I experience side effects?

Most side effects (nausea, diarrhea, constipation) are mild and improve within a few weeks. If side effects are severe or persistent, your provider can:

• Lower your dose
• Slow the rate of dose increases
• Switch you to a different medication
• Recommend anti-nausea medications or dietary modifications

You should contact your provider immediately if you experience severe abdominal pain, persistent vomiting, signs of pancreatitis, or allergic reactions.

Can I travel to another state while on treatment?

Yes, but your provider must be licensed in the state where you’re physically located at the time of your appointment. If you’re planning extended travel, inform your provider in advance. Some telehealth platforms (including Klarity) have multi-state licensure that can accommodate patients who travel frequently.

Are these medications safe for everyone?

No. GLP-1 medications are contraindicated in patients with:

• Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
• Pregnancy or breastfeeding
• History of severe pancreatitis
• Severe gastrointestinal disorders

Your provider will screen for these conditions during your evaluation.

The Future of Telehealth Weight Loss Treatment

Telehealth weight management is not a passing trend—it’s the future of obesity care. As federal and state regulations continue to evolve, we expect:

More States Embracing Full Telehealth Access

States that currently require initial in-person visits may follow the lead of states like California and Washington in allowing fully virtual care for obesity medications.

Permanent Federal Telehealth Rules

The DEA’s temporary telehealth flexibilities expire December 31, 2025, but a fourth extension or new permanent rule is expected. Congress is considering the TREATS Act, which would codify telehealth prescribing flexibilities for controlled substances—signaling broader federal support for virtual care.

Expanded NP/PA Authority

As more states grant Nurse Practitioners full practice authority (currently 34 states plus DC), telehealth platforms can scale more efficiently, reducing wait times and increasing access—especially in underserved areas.

Integration of AI and Remote Monitoring

Future telehealth platforms may incorporate AI-driven health coaching, wearable device integration (e.g., continuous glucose monitors, smart scales), and predictive analytics to personalize treatment and improve outcomes.

Greater Insurance Coverage

As evidence for GLP-1 medications’ effectiveness accumulates, more insurance plans are covering Wegovy and Zepbound for obesity. Medicare may expand coverage in future years, making these medications accessible to millions more Americans.

Final Thoughts: Is Telehealth Weight Loss Right for You?

If you’re struggling with obesity and have been hesitant to seek treatment due to time constraints, privacy concerns, or geographic barriers, telehealth offers a convenient, effective, and medically sound alternative to traditional in-person care.

Telehealth weight loss treatment is right for you if:

• You have a BMI ≥30 (or ≥27 with comorbidities like diabetes or hypertension)
• You’ve tried lifestyle modifications (diet, exercise) without lasting success
• You’re looking for a long-term, evidence-based approach—not a quick fix
• You’re comfortable with self-administered injections and regular virtual check-ins
• You live in a state where telehealth prescribing is permitted (see our state-by-state guide)

Telehealth may NOT be ideal if:

• You have complex medical conditions that require in-person monitoring (e.g., recent bariatric surgery, severe eating disorders)
• You live in a state with strict in-person requirements and can’t access a local provider
• You prefer face-to-face consultations for sensitive health discussions

For most patients, telehealth offers the best of both worlds: expert medical care from the comfort of home, with the flexibility to fit appointments into busy schedules—and the same rigorous safety standards you’d expect from an in-person clinic.

Ready to Start Your Weight Loss Journey with Klarity Health?

At Klarity Health, we believe everyone deserves access to high-quality, compassionate care—no matter where they live or what their schedule looks like. Our licensed providers specialize in weight management and mental health, and we’re here to support you every step of the way.

Here’s how to get started:

1. Visit klarityhealth.com and create a free account
2. Schedule a consultation with a licensed provider in your state (most appointments available within 1-2 days)
3. Complete your medical history through our secure online portal
4. Meet with your provider via live video to discuss your goals and treatment options
5. Receive your prescription electronically and start your personalized treatment plan

Whether you’re exploring GLP-1 medications for the first time or looking for a more convenient way to manage your weight loss treatment, Klarity Health is here to help. Our transparent pricing, flexible scheduling, and expert providers make evidence-based obesity care accessible to everyone.

Take the first step today—because your health journey shouldn’t wait.

Citations and Sources

This article is based on the most current federal and state regulations as of December 17, 2025. Key sources include:

1. Drug Enforcement Administration (DEA) – ‘DEA and HHS Extend Telemedicine Flexibilities through 2025’ (November 15, 2024). Official government announcement confirming extension of temporary telehealth prescribing rules for controlled substances through December 31, 2025. www.dea.gov

2. Axios News – ‘COVID-era telehealth prescribing extended for controlled substances’ (November 18, 2024). News coverage summarizing the DEA’s third extension of pandemic-era telehealth flexibilities. www.axios.com

3. McDermott Will & Emery (Law Firm) – ‘DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025’ (November 18, 2024). Expert legal analysis of current DEA regulations and pending permanent rules. www.mwe.com

4. Goodwin Procter (Law Firm) – ‘Changing Regulatory & Reimbursement Landscape for Weight Loss Drugs’ (March 27, 2024). Comprehensive overview of state-specific prescribing requirements for obesity medications in Florida, New Jersey, Virginia, and other states. www.goodwinlaw.com

5. Nextech (Healthcare Software) – ‘Know Your State’s Laws Around Semaglutide’ (April 11, 2025). State-by-state compilation of prescribing requirements, in-person exam rules, and provider qualifications for GLP-1 medications. www.nextech.com

All federal and state regulatory information has been verified as of December 17, 2025. Healthcare regulations change frequently; patients should always confirm current rules with their provider and state medical board.

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid